10 Best GLP-1 and Weight Loss Stocks to Buy Now

3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Investors: 63

Revenue Growth Rate (year-over-year): 7.76%

Leading biotechnology company Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) uses data insights from the Regeneron Genetics Center and patented technologies like VelociSuite to create novel treatments for serious diseases. They concentrate on conditions related to the eyes, allergies, inflammation, cancer, heart, metabolism, nervous system, hematologic, transmissible, and rare disorders. With an emphasis on maintaining lean mass and decreasing fat mass, the firm is making significant progress in the obesity industry.

A Phase II study for REGN muscle-conserving antibodies is scheduled for mid-2024 as the company prepares to join the enormously profitable obesity market. According to the former CEO George Yancopoulos of REGN, the company’s novel strategy seeks to address the notable muscle loss linked to GLP-1 agonists, which can contribute to over 40% of patients’ weight reduction. Serious public health concerns are raised by this possibly catastrophic and irretrievable risk of muscular atrophy.

Regeneron’s approach combines incretin-based treatments such as tirzepatide and semaglutide with two monoclonal antibodies, trevogrumab and garetosmab. Trevogrumab attaches to activin A, another important factor in muscle atrophy, whereas garetosmab binds to myostatin, a negative regulator of skeletal muscle. Regeneron hopes to enhance the quality of weight reduction in individuals using GLP-1 receptor agonists by obstructing these pathways and maintaining lean muscle mass.

In mid-2024, the company intends to sign up obese patients in the Phase II investigation, subject to the outcome of a safety and tolerability study conducted on healthy volunteers with high-dose trevogrumab. With this strategy, Regeneron may now compete with industry giants, whose obesity therapies similarly target muscle atrophy.

Regeneron Pharmaceuticals (NASDAQ: REGN) has seen a difficult start to 2024, missing sales and EPS projections in the first quarter and getting two comprehensive response letters for odronextamab from the FDA. Notwithstanding these obstacles, Eylea fared well due to the introduction of Eylea HD and the important growth products, Libtayo and Dupixent.

REGN is one of the Best GLP-1 and Weight Loss Stocks to Buy Now. Analysts hold a consensus Buy recommendation on shares. As of the end of the first quarter of 2024, 63 hedge funds out of the 920 funds reported having stakes in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). D E Shaw is the top shareholder with a stake worth $221.83 million.

Regeneron’s stock may rise significantly if the company’s Phase II study for its muscle-preserving antibodies is successful. Risk-tolerant investors can consider doing their due diligence on REGN.